Calcium channel blockers and Raynaud's disease.

Suppr

超能文献

作者信息

Vayssairat M, Capron L, Fiessinger J N, Mathieu J F, Housset E

出版信息

Ann Intern Med. 1981 Aug;95(2):243. doi: 10.7326/0003-4819-95-2-243_2.

DOI:10.7326/0003-4819-95-2-243_2

PMID:6266305

Abstract

摘要

相似文献

Calcium channel blockers and Raynaud's disease.

Ann Intern Med. 1981 Aug;95(2):243. doi: 10.7326/0003-4819-95-2-243_2.

A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.

J Rheumatol. 1985 Aug;12(4):724-7.

Diltiazem and Raynaud's syndrome.

Ann Intern Med. 1982 Sep;97(3):455.

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.

Ann Rheum Dis. 1985 Jan;44(1):30-3. doi: 10.1136/ard.44.1.30.

Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.

Am J Cardiol. 1985 Jan 25;55(3):154B-157B. doi: 10.1016/0002-9149(85)90625-3.

Treatment of Raynaud's phenomenon with calcium channel blockers.

Am J Med. 1985 Feb 22;78(2B):39-42. doi: 10.1016/0002-9343(85)90168-8.

Effects of diltiazem on occupational Raynaud's syndrome (vibration disease).

Angiology. 1985 Dec;36(12):850-6. doi: 10.1177/000331978503601203.

Some extracardiac effects of diltiazem and other calcium entry blockers.

Acta Pharmacol Toxicol (Copenh). 1985;57 Suppl 2:31-43. doi: 10.1111/j.1600-0773.1985.tb03572.x.

Rational use of calcium-channel antagonists in Raynaud's phenomenon.

Curr Opin Rheumatol. 1998 Nov;10(6):584-8. doi: 10.1097/00002281-199811000-00013.

[Calcium antagonists and Raynaud's phenomenon].

Therapie. 1993 Nov-Dec;48 Spec No:707-11.

引用本文的文献

Limb ischemia caused by small artery disease.

World J Surg. 1983 May;7(3):326-33. doi: 10.1007/BF01658080.

The peripheral vascular effects of diltiazem--dose-response characteristics.

Br J Clin Pharmacol. 1985 Nov;20(5):447-51. doi: 10.1111/j.1365-2125.1985.tb05095.x.

Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Drugs. 1985 May;29(5):387-454. doi: 10.2165/00003495-198529050-00001.

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.

Ann Rheum Dis. 1985 Jan;44(1):30-3. doi: 10.1136/ard.44.1.30.

Nisoldipine in primary Raynaud's phenomenon.

Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.

Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Drugs. 1987 Jun;33(6):531-8. doi: 10.2165/00003495-198733060-00001.

Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750.

Management of Raynaud's phenomenon. Focus on newer treatments.

Drugs. 1989 May;37(5):700-12. doi: 10.2165/00003495-198937050-00005.

Pathogenesis and treatment of Raynaud's phenomenon.

Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:45-51. doi: 10.1007/BF00053426.

Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Drugs. 1990 May;39(5):757-806. doi: 10.2165/00003495-199039050-00009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Calcium channel blockers and Raynaud's disease.

Ann Intern Med. 1981 Aug;95(2):243. doi: 10.7326/0003-4819-95-2-243_2.

A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.

J Rheumatol. 1985 Aug;12(4):724-7.

Diltiazem and Raynaud's syndrome.

Ann Intern Med. 1982 Sep;97(3):455.

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.

Ann Rheum Dis. 1985 Jan;44(1):30-3. doi: 10.1136/ard.44.1.30.

Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.

Am J Cardiol. 1985 Jan 25;55(3):154B-157B. doi: 10.1016/0002-9149(85)90625-3.

Treatment of Raynaud's phenomenon with calcium channel blockers.

Am J Med. 1985 Feb 22;78(2B):39-42. doi: 10.1016/0002-9343(85)90168-8.

Effects of diltiazem on occupational Raynaud's syndrome (vibration disease).

Angiology. 1985 Dec;36(12):850-6. doi: 10.1177/000331978503601203.

Some extracardiac effects of diltiazem and other calcium entry blockers.

Acta Pharmacol Toxicol (Copenh). 1985;57 Suppl 2:31-43. doi: 10.1111/j.1600-0773.1985.tb03572.x.

Rational use of calcium-channel antagonists in Raynaud's phenomenon.

Curr Opin Rheumatol. 1998 Nov;10(6):584-8. doi: 10.1097/00002281-199811000-00013.

[Calcium antagonists and Raynaud's phenomenon].

Therapie. 1993 Nov-Dec;48 Spec No:707-11.

引用本文的文献

Limb ischemia caused by small artery disease.

World J Surg. 1983 May;7(3):326-33. doi: 10.1007/BF01658080.

The peripheral vascular effects of diltiazem--dose-response characteristics.

Br J Clin Pharmacol. 1985 Nov;20(5):447-51. doi: 10.1111/j.1365-2125.1985.tb05095.x.

Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Drugs. 1985 May;29(5):387-454. doi: 10.2165/00003495-198529050-00001.

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.

Ann Rheum Dis. 1985 Jan;44(1):30-3. doi: 10.1136/ard.44.1.30.

Nisoldipine in primary Raynaud's phenomenon.

Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.

Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Drugs. 1987 Jun;33(6):531-8. doi: 10.2165/00003495-198733060-00001.

Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750.

Management of Raynaud's phenomenon. Focus on newer treatments.

Drugs. 1989 May;37(5):700-12. doi: 10.2165/00003495-198937050-00005.

Pathogenesis and treatment of Raynaud's phenomenon.

Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:45-51. doi: 10.1007/BF00053426.

Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Drugs. 1990 May;39(5):757-806. doi: 10.2165/00003495-199039050-00009.